Keywords: AstraZeneca, Crestor, FDA, Indications, Heart attack, Stroke, Cancer metabolism drug research, Cancer Resarch UK
AstraZeneca gets wider US indications for Crestor; enters cancer drug development deal with UK charity
Article | 09 February 2010
The US Food and Drug Administration yesterday approved Anglo-Swedish drug major AstraZeneca’s blockbuster cholesterol-lowerer Crestor (rosuvastatin calcium) for additional ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
